SERPINA6

Corticosteroid-binding globulin · P08185 · SERPINA6 on Sugi Atlas →

48,234 patent compounds predicted against SERPINA6, 38,971 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Methyltestosterone (SCHEMBL18657)	0.74	7/20
SCHEMBL24461	0.57	7/20
Cortodoxone (SCHEMBL42590)	1.00	6/20
SCHEMBL141610	0.80	6/20
SCHEMBL141611	0.80	6/20
SCHEMBL141582	0.71	6/20
SCHEMBL148415	0.69	6/20
SCHEMBL8069	0.67	6/20
Algestone Acetonide (SCHEMBL42582)	0.62	6/20
Progesterone (SCHEMBL7671)	1.00	5/20
Hydroxyprogesterone (SCHEMBL8068)	1.00	5/20
SCHEMBL26178	1.00	5/20
SCHEMBL142942	1.00	5/20
Hydroxyprogesterone (SCHEMBL265609)	1.00	5/20
Progesterone (SCHEMBL220821)	0.95	5/20
Hydrocortisone (SCHEMBL24460)	0.81	5/20
SCHEMBL143924	0.79	5/20
SCHEMBL144474	0.79	5/20
Cortisone Acetate (SCHEMBL4501)	0.78	5/20
SCHEMBL144490	0.78	5/20

Clinical trials — most relevant to SERPINA6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills	PHASE4	COMPLETED
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer	PHASE3	RECRUITING
A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome	PHASE2/PHASE3	RECRUITING
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
Serplulimab Combined With CCRT for LS-SCLC.	PHASE2	RECRUITING
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC	PHASE2	RECRUITING
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC	PHASE2	UNKNOWN
Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study	PHASE2	COMPLETED
Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS	PHASE2	COMPLETED
High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children	PHASE2	RECRUITING
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer	PHASE2	UNKNOWN
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer	PHASE2	NOT_YET_RECRUITING
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Mass Spectrometry Based Cutoffs for Cortisol After Stimulation Tests	nan	COMPLETED
Objective Markers and New Indicators in AI Disease (OMNI-AID Study)	nan	UNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency	nan	COMPLETED
Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome	nan	RECRUITING
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests	nan	UNKNOWN
Does Relative Hypoglycaemia &/or Sleep Disturbance Contribute to the Lethargy Observed in Addison's Disease	nan	UNKNOWN
Cortisol, Hippocampus, and Insula in Anorexia Nervosa.	nan	RECRUITING
Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases	nan	COMPLETED
Thyroid and Cortisol Hormone Response to Sepsis	nan	NOT_YET_RECRUITING
Effect of Aromatase Inhibitors on Bones and Genes	nan	COMPLETED
Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients	nan	UNKNOWN
Biomarkers in Idiopathic Juvenile Arthritis	nan	UNKNOWN
Determinants of Vascular Leakage During Systemic Inflammatory Response Syndrome	nan	RECRUITING
Proadrenomedullin for Early Risk Assessment in the Emergency Department	nan	COMPLETED
Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis	nan	COMPLETED
Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SERPINA6 binder may also engage these)

Protein	Name	Similarity
Q5R9E3	—	1.000	Q5R9E3 →
P05543	—	0.998	P05543 →
P23775	—	0.997	P23775 →
E1BF81	—	0.996	E1BF81 →
B2D1U1	—	0.995	B2D1U1 →
Q9GK37	—	0.994	Q9GK37 →
P50451	—	0.994	P50451 →
P61640	—	0.993	P61640 →
P49920	—	0.992	P49920 →
Q91WP6	—	0.991	Q91WP6 →
Q5R536	—	0.990	Q5R536 →
P29621	—	0.989	P29621 →
Q9N2I2	—	0.989	Q9N2I2 →
P07759	—	0.989	P07759 →
O54762	—	0.989	O54762 →
Q9D7D2	—	0.988	Q9D7D2 →
A2I7N3	—	0.988	A2I7N3 →
Q9TTE1	—	0.988	Q9TTE1 →
P22324	—	0.988	P22324 →
Q80X76	—	0.988	Q80X76 →
P31211	—	0.988	P31211 →
Q63556	—	0.987	Q63556 →
P29622	—	0.986	P29622 →
Q00898	—	0.986	Q00898 →
A2I7N2	—	0.986	A2I7N2 →
P05545	—	0.986	P05545 →
Q03734	—	0.985	Q03734 →
Q60396	—	0.985	Q60396 →
Q5I2A0	—	0.985	Q5I2A0 →
A6QPQ2	—	0.984	A6QPQ2 →